Results 71 to 80 of about 20,060 (180)

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Early viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient

Clinics and Practice, 2011
Genotype 5 hepatitis C has been poorly studied despite its worldwide spread. We have analyzed the early kinetics of genotype 5 hepatitis C virus RNA during pegylated interferon/ribavirin treatment in a 59-year-old man with active liver necroinflammatory ...
Emanuele Durante-Mangoni, Domenico Iossa, Umberto Malgeri   +2 more
doaj   +1 more source

Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia

Gastroenterology Research and Practice, 2016
Aim. To evaluate the compliance and virological response to pegylated interferon alpha 2a treatment of chronic hepatitis B in Roma population compared to majority Caucasian population in Slovakia. Methods. Retrospective evaluation of a cohort of all Roma
Sylvia Drazilova, Martin Janicko, Pavol Kristian, Ivan Schreter, Branislav Kucinsky, Marek Kozlej, Ivana Hockickova, Peter Jarcuska   +7 more
doaj   +1 more source

Diagnosis and treatment of viral liver fibrosis

The Saudi Journal of Gastroenterology, 2005
This review summarized the diagnostic value of fibrosis biomarkers and the efficacy of anti-viral treatments on fibrosis progression. Non-invasive biomarkers can facilitate the screening and management of chronic hepatitis C and B.
Poynard Thierry, Imbert-Bismut Francoise, Munteanu Mona, Ratziu Vlad   +3 more
doaj  

Psychosis during peginterferon-alpha2a and ribavirin therapy: case report

Brazilian Journal of Infectious Diseases
Pegylated Interferon-alpha, combined with ribavirin, gives high sustained virological response in patients with hepatitis C virus, an important public health problem and one of the most frequent chronic infectious diseases worldwide.
Lucas C. Quarantini, Simone Cunha Cruz, Susana Carolina Batista-Neves, Raymundo Paraná, Ângela Miranda-Scippa, Rodrigo A. Bressan   +5 more
doaj   +1 more source

Interferons in the treatment of myeloproliferative neoplasms

Therapeutic Advances in Hematology
Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years.
Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M. Palmer, Aaron T. Gerds, Lucia Masarova, Andrew T. Kuykendall, Raajit K. Rampal, Ruben Mesa, Srdan Verstovsek   +11 more
doaj   +1 more source

Pegylated Interferon Alfa [PDF]

, 2020
openaire   +1 more source

Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis. [PDF]

Cancers (Basel)
Machherndl-Spandl S, Kiehberger M, Sygulla V, Kaynak E, Zach O, Webersinke G, Gruber-Rossipal C, Beham-Schmid C, Maier E, Strassl I, Clausen J, Nikoloudis A, Schimetta W, Rumpold H, Buxhofer-Ausch V.   +14 more
europepmc   +1 more source

Safety evaluation and toxicokinetics of repeated inhalation exposure to pegylated interferon α-2b. [PDF]

Front Pharmacol
Ji C, Ji X, Li H, Wang Q.
europepmc   +1 more source

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms. [PDF]

Blood Adv
Davidsen ID, Larsen MK, Löffler L, Skov V, Kjær L, Knudsen TA, Sørensen AL, Christensen SF, Cordua S, Eickhardt-Dalbøge CS, Kristiansen MH, Ellervik C, Wienecke T, Hasselbalch HC.   +13 more
europepmc   +1 more source